
|Articles|March 1, 2003
So Far, So Good
Paris - Citing ease of application and time savings as the key advantages, Jean-Marie Lachapelle, M.D., characterized Allerderm's T.R.U.E. Test as "a step forward in the technology of patch testing that ensures an optimal penetration and delivery of allergens through the skin."
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population
2
Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC
3
Phase 2 Nemolizumab Trial Opens for CPUO
4
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
5


















